Latest On Editas Medicine, Inc (EDIT):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-18 19:53 EST | News | Editas Medicine strengthens board of directors with appointment of new chair and new director | N/A |  |
| 2023-05-17 02:54 EST | News | Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference 2023 Transcript | N/A | |
| 2023-05-17 02:54 EST | News | Editas Medicine appoints Erick Lucera as CFO, Michelle Robertson steps down | N/A | |
| 2023-05-14 04:40 EST | News | Editas Medicine, Inc. (EDIT) Bank of America Global Healthcare Conference Call Transcript | N/A | |
| 2023-05-06 02:18 EST | News | Editas Medicine, Inc. (EDIT) Q1 2023 Earnings Call Transcript | N/A | |
About Editas Medicine, Inc (EDIT):
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is develo read more...ping gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
General
- Name Editas Medicine, Inc
- Symbol EDIT
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 235
- Fiscal Year EndDecember
- IPO Date2016-02-03
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.editasmedicine.com
Valuation
- Price/Sales (Trailing 12 Mt.) 26.85
- Price/Book (Most Recent Quarter) 6.25
- Enterprise Value Revenue 25.23
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$3.34
- Next Year EPS Estimate -$3.49
- Next Quarter EPS Estimate -$0.78
- Profit Margin -128%
- Operating Margin -149%
- Return on Assets -16%
- Return on Equity -35%
- Revenue 90.73 million
- Earnings Per Share -$2.14
- Revenue Per Share $1.55
- Gross Profit -67264000
- Quarterly Earnings Growth -7%
Highlights
- Market Capitalization 2.91 billion
- EBITDA -106383000
- PE Ratio -1.59
- Analyst Target Price $52.83
- Book Value Per Share $6.29
Share Statistics
- Shares Outstanding 67.36 million
- Shares Float 66.37 million
- % Held by Insiders 137%
- % Held by Institutions 82.21%
- Shares Short 11.31 million
- Shares Short Prior Month 9.84 million
- Short Ratio 4.22
- Short % of Float 17%
- Short % of Shares Outstanding 17%
Technicals
- Beta 2.08
- 52 Week High $99.95
- 52 Week Low $18.2
- 50 Day Moving Average 52.94
- 200 Day Moving Average 46.49
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Editas Medicine, Inc (EDIT) Dividend Calendar:
Editas Medicine, Inc (EDIT) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Editas Medicine, Inc (EDIT) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Editas Medicine, Inc (EDIT) Chart:
Editas Medicine, Inc (EDIT) News:
Below you will find a list of latest news for Editas Medicine, Inc (EDIT) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Editas Medicine, Inc (EDIT) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest EDIT Trades:
Editas Medicine, Inc (EDIT) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-05 | 8-K (Current report) | |
| 2020-10-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-09 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-08-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-07 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-07-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-25 | 8-K (Current report) | |
| 2020-06-25 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-06-25 | 8-K (Current report) | |
| 2020-06-23 | S-3ASR (Automatic shelf registration statement of securities of well-known seasoned issuers) | |
| 2020-06-15 | 8-K (Current report) | |
| 2020-06-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-12 | 4 (Statement of changes in beneficial ownership of securities) | |
Editas Medicine, Inc (EDIT) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Editas Medicine, Inc (EDIT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 137%
Institutional Ownership: 8221%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-10-15 | Charles Albright | EVP/Chief Scientific Officer | Sell | 3,000.00 | 31.39 | 94,170.00 | 25,135.00 | |
| 2020-08-20 | Cynthia Collins | CEO | Sell | 1,976.00 | 36.66 | 72,440.16 | 45,022.00 | |
| 2020-08-17 | Charles Albright | EVP/Chief Scientific Officer | Sell | 10,000.00 | 35.29 | 352,900.00 | 28,135.00 | |
| 2020-08-17 | Charles Albright | EVP/Chief Scientific Officer | Buy | 10,000.00 | 16.51 | 165,100.00 | 38,135.00 | |
| 2020-08-07 | Charles Albright | EVP/Chief Scientific Officer | Sell | 238.00 | 34.99 | 8,327.62 | 28,135.00 | |
| 2020-08-06 | Charles Albright | EVP/Chief Scientific Officer | Sell | 10,000.00 | 37.47 | 374,700.00 | 28,373.00 | |
| 2020-08-06 | Charles Albright | EVP/Chief Scientific Officer | Buy | 10,000.00 | 16.51 | 165,100.00 | 38,373.00 | |
| 2020-07-15 | Charles Albright | EVP/Chief Scientific Officer | Sell | 3,000.00 | 32.22 | 96,660.00 | 28,373.00 | |
| 2020-05-06 | Charles Albright | EVP/Chief Scientific Officer | Sell | 151.00 | 25.28 | 3,817.28 | 31,373.00 | |
| 2020-02-07 | Charles Albright | Chief Scientific Officer | Sell | 622.00 | 26.95 | 16,762.90 | 31,524.00 | |
| 2020-02-06 | Charles Albright | Chief Scientific Officer | Buy | 11,593.00 | 32,146.00 | | ||
| 2020-02-06 | Cynthia Collins | CEO | Buy | 15,625.00 | 46,998.00 | | ||
| 2020-02-03 | Charles Albright | Chief Scientific Officer | Sell | 5,549.00 | 26.54 | 147,287.66 | 20,553.00 | |
| 2020-01-31 | Charles Albright | Chief Scientific Officer | Buy | 17,977.00 | 26,102.00 | | ||
| 2020-01-09 | MICHELLE ROBERTSON | Chief Financial Officer | Buy | 20,000.00 | 20,000.00 | | ||
| 2019-10-28 | Judith R Abrams | Chief Medical Officer | Buy | 25,000.00 | 25,000.00 | | ||
| 2019-09-11 | Cynthia Collins | CEO | Buy | 20,000.00 | 31,373.00 | | ||
| 2019-08-19 | Cynthia Collins | CEO | Sell | 5,193.00 | 25.83 | 134,135.19 | 11,373.00 | |
| 2019-08-19 | Cynthia Collins | CEO | Buy | 8,283.00 | 16,566.00 | | ||
| 2019-08-06 | Cynthia Collins | CEO | Buy | 8,283.00 | 16,566.00 | |